12th IMPACCT RWE Summit 2024

Digitalization and centralization of datasets have vastly increased the volume of RWD. Advances in AI, deep learning, and large language models have revolutionized big data analysis. Payers and regulators are prioritizing RWE in submissions. These three revolutions are driving a boom in RWE. However, questions remain for clinical, regulatory, and HEOR experts on how to best leverage and disseminate this data.

Join us at the 12th IMPACCT Real World Evidence Summit, the premier industry event dedicated to uniting RWE and Evidence Generation experts. This is your opportunity to innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.

URLs:
Website: https://go.evvnt.com/2495675-0?pid=10018
Brochure: https://go.evvnt.com/2495675-2?pid=10018
Tickets: https://go.evvnt.com/2495675-3?pid=10018

Prices:
Drug Developer - Conference + Workshop Day: USD 4197.00,
Drug Developer - Conference Only: USD 2999.00,
Academic - Conference + Workshop Day: USD 3597.00,
Academic - Conference Only: USD 2599.00,
Service Provider - Conference + Workshop Day: USD 5097.00,
Service Provider - Conference Only: USD 3699.00

Speakers: Amit Raval, Director - Real-World Evidence Oncology, Bayer, Andrew Goldberg, Chief Operating Officer, HealthVerity, Barry Grau, Senior Manager - Real World Analytics, Vertex Pharmaceuticals, Daina Esposito, Executive Director, Global Safety Epidemiology, Real World Evidence, Moderna, Eugean Jiwanmall, Senior Research Analyst for Medical Policy and Technology Evaluation, Independence Blue Cross, Griffith Bell, Director - Real World Evidence Biostatistics, Pfizer, Hairong Xu, Executive Director - Global Medical Affairs and Clinical Development, Kite Pharma Inc, Haoda Fu, Associate Vice President - Enterprise Lead Machine Learning and AI, Eli Lilly and Co., Hemanth Kanakamedala, Senior Director - Real World Evidence and Advanced Analytics, Janssen, Ipek Ozer Stillman, Head of Global Health Economics, Payer Value and Patient Access, Takeda Pharmaceutical Co. Ltd., Jason Lott, Vice President - Global Integrated Evidence Generation, Specialty Medicine, Integrated Care, and Cell-Gene Therapy, Bayer, Jeannette Green, Senior Clinical Study Lead, Real World Evidence, Regeneron, Joseph Cappelleri, Executive Director - Biostatistics, Pfizer, Kelly Zou, Head, Global Medical Analytics, Real World Evidence Health Economics and Outcomes Research, Viatris, Lucas Oliveira, Director, Real World Evidence and Strategy, Chiesi Inc., Madison Rudow, Manager, RWE Operations, Rare Diseases, Chiesi SAS, Mawuli Nyaku, Strategy Head, Immunology and Communicable Diseases, Data Science and Digital Health, JNJ Innovative Medicine, Miriam Kore, Executive Director, Therapeutic Area Operations Leader, Real World Evidence, Regeneron Pharmaceuticals Inc, Orsolya Lunacsek, Real World Data Strategy and Innovation Lead, Bayer, Philippe Auvaro, Executive Director, EBM Overseas Business, MDV, Roberto Araujo, Head of Global Evidence Generation Strategy and Rare Diseases, Sanofi, Siddharth Jain, Medical Director - Global Medical Lead Lysosomal Storage Diseases, Takeda, Witney Baah, Associate Director, Real World Value and Evidence, Partnerships, Data and Platforms, Johnson and Johnson, XiaoLong Jiao, Senior Director, RWE, Pfizer, Yong Chen, Senior Director, Real World Evidence, Oncology, Pfizer, Zhenyi Xue, Director, RWE Statistics, Incyte Corporation